Active substance
Lisdexamfetamine dimesilate
- SFDA 6
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Vyvanse | 20 mg | Capsule, hard · Oral use | 30 Bottle | SAR 317.65 | NCE · Prescription | Takeda Pharmaceuticals International AG | Valid |
| Vyvanse | 30 mg | Capsule, hard · Oral use | 30 Bottle | SAR 340.30 | NCE · Prescription | Takeda Pharmaceuticals International AG | Valid |
| Vyvanse | 40 mg | Capsule, hard · Oral use | 30 Bottle | SAR 363.00 | NCE · Prescription | Takeda Pharmaceuticals International AG | Valid |
| Vyvanse | 50 mg | Capsule, hard · Oral use | 30 Bottle | SAR 383.40 | NCE · Prescription | Takeda Pharmaceuticals International AG | Valid |
| Vyvanse | 60 mg | Capsule, hard · Oral use | 30 Bottle | SAR 399.30 | NCE · Prescription | Takeda Pharmaceuticals International AG | Valid |
| Vyvanse | 70 mg | Capsule, hard · Oral use | 30 Bottle | SAR 408.40 | NCE · Prescription | Takeda Pharmaceuticals International AG | Valid |
Indications — CHI Daman Drug Formulary
ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD); AUTISM SPECTRUM DISORDER
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.